200 Chapter 9 Table 4. Characteristics of patients with baseline ECG abnormalities without physical complaints during 12 months follow-up. Sex Age (years) BMI (kg/m2) Diagnosis CGRP-(R-) Mab CVD history Baseline 3 months 6 months 9 months 12 months Conclusion 1 F 39 20.1 MA Erenumab None Right heart axis Right heart axis Right heart axis Right heart axis Right heart axis No intervention 2 F 63 27.5 MA Erenumab Hypertension AV-block grade I AV-block grade I, mild hypertension AV-block grade I, moderate hypertension AV-block grade I, mild hypertension Normal, mild hypertension No intervention 3 M 49 21.6 MA Erenumab Congenital aorta valve insufficiency Left heart axis, LVH Left heart axis, LVH Left heart axis, LVH * Left heart axis, LVH No intervention 4 M 56 28.7 MO Erenumab None AV-block grade I AV-block grade I, mild hypertension AV-block grade I, mild hypertension AV-block grade I AV-block grade I, mild hypertension No intervention 5 M 48 21.9 MA Erenumab Biphasic P-wave, no abnormalities found on echocardiography Biphasic P-wave Biphasic P-wave, moderate hypertension Biphasic P-wave, mild hypertension *, severe hypertension *, severe hypertension Start of antihypertensive medication 6 M 47 22.1 MO Erenumab None RBBB RBBB, mild hypertension * RBBB RBBB Cardiologist: no objection to continuing CGRP-R-Mab 7 F 52 23.0 MA Erenumab None Left heart axis * Left heart axis Normal ECG, mild hypertension Left heart axis No intervention 8 F 61 18.9 MA Erenumab None Right heart axis Right heart axis Right heart axis Right heart axis Right heart axis Cardiologist: benign variant 9 F 41 22.5 MO Fremanezumab None Left anterior fascicular block Left anterior fascicular block Left anterior fascicular block Left anterior fascicular block Left anterior fascicular block Cardiologist: no objection to continuing CGRP-Mab 10 F 47 24.7 MO Fremanezumab Wolff-ParkinsonWhite (WPW) syndrome AV-block grade I Normal ECG Normal ECG Normal ECG Normal ECG No intervention 11 F 26 18.8 MA Fremanezumab None PAC PAC PAC PAC Left posterior fascicular block Cardiologist: no objection to continuing CGRP-Mab 12 F 68 19.9 MO Fremanezumab None RBBB RBBB RBBB RBBB RBBB Cardiologist: no objection to continuing CGRP-Mab 13 F 49 25.5 MA Fremanezumab None Left heart axis Left heart axis Left heart axis Left heart axis * Cardiologist: no objection to continuing CGRP-Mab CVD = cardiovascular disease, CGRP-Mab = Calcitonin Gene Related Peptide - Monoclonal antibody, F = female, LAH = left atrium hypertrophy, LVH = left ventricular hypertrophy, M = male, MA = migraine with aura, MO = migraine without aura, PAC = premature atrial complex, RBBB = right bundle branch block. * = (random) missing data, ¶ = missing due to discontinuation of treatment.
RkJQdWJsaXNoZXIy MjY0ODMw